In this article, we will look at the 13 Best Growth Stocks Under $25 to Buy Right Now.
Recently, there have been concerns around the surge of fraudulent loans and private credit quality issues in the US. This comes as several US regional banks disclosed exposure to potentially fraudulent loans. Jamie Dimon, CEO of JPMorgan Chase, has expressed caution, noting that this could signal deeper systemic stress that may impact the broader financial system.
However, on October 17, Marc Pinto, Head of Global Private Credit at Moody’s, noted that there’s little evidence of any systematic problem. He acknowledged that there are some concerns regarding loose lending standards; however, he does not think that issues like these can trigger broader financial crises.
On October 18, Tom Lee from Fundstrat Joined CNBC Television to discuss the latest headlines related to private credit quality issues and their impact on the market. Lee noted that he is inclined more towards Jamie Dimon’s camp and believes that there is opacity in the private credit, and investors would have to grapple with this problem. He noted that this new headline, along with the trade tensions and the increase in VIX, is causing investors to stay cautious.
Regardless, Lee remains bullish and noted that these new headlines do not change the fact that the market has a lot of tailwinds into year-end. He believes a part of this tailwind is due to the accelerating demand for AI, along with a lot of cash sitting on the sidelines. Lee noted that in addition to these tailwinds, institutional investors have had a troubled year with only a 22% return, hardly beating their benchmark, which puts them at a chasing position. Therefore, Lee believes that despite the mounting pressure from these headlines, the market is still set to rally into the end of the year.
With that, let’s take a look at the 13 Best Growth Stocks Under $25 to Buy Right Now.
Our Methodology
To curate the list of 13 Best Growth Stocks Under $25 to Buy Right Now, we used the Finviz Stock Screener, Yahoo Finance, and Insider Monkey’s Q2 2025 database as our sources. Using the screener, we aggregated a list of growth stocks trading below $25, sorted by market capitalization. Next, we cross-checked the stock prices from Yahoo Finance and ranked the stocks in ascending order of the number of hedge fund holders sourced from Insider Monkey’s database. Please note that the data was recorded on October 17, 2025.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).
13 Best Growth Stocks Under $25 to Buy Right Now
13. Takeda Pharmaceutical Company Limited (NYSE:TAK)
Price: $13.95
Number of Hedge Fund Holders: 18
Takeda Pharmaceutical Company Limited (NYSE:TAK) is one of the Best Growth Stocks Under $25 to Buy Right Now. On October 14, Reuters reported that Takeda Pharmaceutical Company Limited (NYSE:TAK) and US biotechnology company Nabla Bio signed a major research partnership. The partnership is focused on deepening the use of AI to accelerate drug delivery.
This partnership builds on an earlier collaboration, which was launched between the two companies in 2022. As part of this partnership, Nabla will use its proprietary AI platform called the Joint Atomic Model (JAM) to design protein-based treatments for Takeda Pharmaceutical Company Limited’s (NYSE:TAK) early-stage pipeline.
As per the report, the company will pay an upfront payment in double-digit millions to Nabla, whereas Nabla would also be eligible for success-based payments worth more than $1 billion. The CEO of Nabla, Surge Biswas, noted that JAM would respond to molecular queries similar to how ChatGPT answers questions.
Takeda Pharmaceutical Company Limited (NYSE:TAK) is a Japanese biotech company that specializes in the research, development, and sale of pharmaceuticals. The company focuses on gastrointestinal, rare, immune, cancer, and neuropsychiatric diseases.
12. SoundHound AI, Inc. (NASDAQ:SOUN)
Price: $19.75
Number of Hedge Fund Holders: 19
SoundHound AI, Inc. (NASDAQ:SOUN) is one of the Best Growth Stocks Under $25 to Buy Right Now. On October 13, SoundHound AI, Inc. (NASDAQ:SOUN) announced partnering with Apivia Courtage, which is part of AEMA Group.
The partnership is aimed at the launch of Amelia 7 across Apivia’s contact centers. Amelia 7 is SoundHound AI, Inc.’s (NASDAQ:SOUN) latest agentic AI platform. Using the company’s latest platform, Apivia will automate its inbound calls with AI agents.
Management noted that Amelia 7 integrates the company’s speech recognition with the Agentic+ framework, which is powered by LLM. This allows the new platform to have natural language understanding and combines this feature with the traditional workforce, along with allowing human escalation when required.
SoundHound AI, Inc. (NASDAQ:SOUN) develops conversational intelligence solutions that enable businesses to create voice-activated experiences for customers across various industries.
11. SailPoint, Inc. (NASDAQ:SAIL)
Price: $21.61
Number of Hedge Fund Holders: 27
SailPoint, Inc. (NASDAQ:SAIL) is one of the Best Growth Stocks Under $25 to Buy Right Now. On October 17, Peter Levine from Evercore ISI reiterated a Buy rating on SailPoint, Inc. (NASDAQ:SAIL) with a price target of $29.
Earlier on October 2, Keith Bachman from BMO Capital also reiterated a Buy rating on the stock with a price target of $25. SailPoint, Inc. (NASDAQ:SAIL) is set to benefit from the expanding role of AI, said the analyst in a research note. He referred to the company’s latest product announcements for enhancing upsell and cross-sell opportunities as an instance of the company’s role in the AI industry. Bachman also likes its Atlas Platform, which he believes sets the company apart from competitors due to its capability of managing human and agent identities.
The analyst highlighted SailPoint, Inc. (NASDAQ:SAIL), which governs over 125 million identities, referring to the company’s scale. He noted that its latest products, such as the Agent Identity Security, solidify the company’s market position further.
SailPoint, Inc. (NASDAQ:SAIL) provides enterprise identity security solutions by unifying identity data across employees, contractors, machines, and AI agents.
10. Haleon plc (NYSE:HLN)
Price: $9.38
Number of Hedge Fund Holders: 30
Haleon plc (NYSE:HLN) is one of the Best Growth Stocks Under $25 to Buy Right Now. On October 8, David Hayes from Jefferies maintained a Buy rating on Haleon plc (NYSE:HLN) with a price target of p440.
The analyst noted several factors which are expected to improve the company’s performance, including easier sale comparisons in Latin America, positive impact of innovation in Europe and other emerging markets, along with stabilization in the North America. As a result, the analyst forecasts the company’s organic sales to grow at 3.4% during FQ3 2025 and raised his forecast to 3.6% growth in FQ4. He remains optimistic in Haleon plc’s (NYSE:HLN) growth potential and expects the company to accelerate growth in 2026.
In addition to Jefferies, on October 10, Barclays analyst Warren Ackerman maintained a Hold rating on Haleon plc (NYSE:HLN) with a price target of p380.
Haleon plc (NYSE:HLN) is a consumer healthcare company offering a wide range of products across six major categories, such as oral health, vitamins, pain relief, respiratory, digestive, and skin health.
9. Summit Therapeutics Inc. (NASDAQ:SMMT)
Price: $21.56
Number of Hedge Fund Holders: 30
Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the Best Growth Stocks Under $25 to Buy Right Now. On October 17, Summit Therapeutics Inc. (NASDAQ:SMMT) announced the expansion of its Phase 3 clinical development program called HARMONi-GI3, for its candidate Ivonescimab.
Ivonescimab is a novel biospecific antibody that combines with chemotherapy in patients with unresectable metastatic colorectal cancer. The phase 3 trials will compare ivonescimab plus chemotherapy with bevacizumab plus chemotherapy as first-line therapy for patients with CRC. Management noted that the trial is global and they aim to enroll around 600 patients. Trial sites in the United States are expected to start soon.
Summit Therapeutics Inc. (NASDAQ:SMMT) is a biotechnology company that is focused on developing therapies mainly for cancer treatment.
8. Informatica Inc. (NYSE:INFA)
Price: $24.84
Number of Hedge Fund Holders: 35
Informatica Inc. (NYSE:INFA) is one of the Best Growth Stocks Under $25 to Buy Right Now. On October 14, Informatica Inc. (NYSE:INFA) announced four new integrations on Oracle Cloud Infrastructure. When integrated, these new solutions will help Oracle customers to unify and manage master data from Oracle and non-Oracle sources.
These new integrations include Blueprint for Agentic AI on OCI, IDMC MCP Server Support, Master Data Management (MDM) Capability on OCI, and Informatica’s Intelligent Data Management Cloud on OCI Dedicated Region.
Rik Tamm-Daniels, GVP, Ecosystems & Technology of Informatica Inc. (NYSE:INFA) noted that by bringing these new integrations to Oracle Cloud, they are giving Oracle customers a fast route to intelligent, high-quality, and trusted data for AI across all cloud environments.
Informatica Inc. (NYSE:INFA) is an enterprise AI-powered cloud management company. The company operates the Informatica Intelligent Data Management Cloud platform and is also an Oracle Partner.
7. UiPath Inc. (NYSE:PATH)
Price: $15.75
Number of Hedge Fund Holders: 42
UiPath Inc. (NYSE:PATH) is one of the Best Growth Stocks Under $25 to Buy Right Now. On October 10, Jake Roberge from William Blair maintained a Hold rating on UiPath Inc. (NYSE:PATH) without disclosing any price target.
The rating comes after the firm met with the company’s management. Roberge noted the company highlighted adopting new AI solutions and forming new partnerships with major companies, including OpenAI, Nvidia, and Snowflake. The analyst noted that these are significant milestones for the company but are still in early stages.
UiPath Inc. (NYSE:PATH) also discussed its adjustments to the company’s go-to-market strategy and the current demand situation in the industry, particularly within the public sector. The analyst highlighted that while the overall trajectory of the company is positive, the overall impact on the financial performance is still uncertain, thereby justifying his neutral stance.
UiPath Inc. (NYSE:PATH) is an enterprise automation and AI company that uses robotic process automation and computer vision technology to automate tasks for businesses.
6. Roivant Sciences Ltd. (NASDAQ:ROIV)
Price: $17.09
Number of Hedge Fund Holders: 54
Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the Best Growth Stocks Under $25 to Buy Right Now. Wall Street has a mixed opinion on Roivant Sciences Ltd. (NASDAQ:ROIV) since the company announced positive results from its Phase 3 VALOR study testing Brepocitinib in dermatomyositis on September 17.
On October 8, Brian Cheng from J.P. Morgan reiterated a Buy rating on Roivant Sciences Ltd. (NASDAQ:ROIV) with a price target of $20. However, earlier on September 24, Chi Meng Fong from Bank of America Securities had reiterated a Hold rating on the stock with a $16.5 price target.
Fong noted the company has shown promising progress in its Phase 3 VALOR study. However, he anticipates the launch targeting only a limited referral center, thereby limiting the immediate growth potential as well.
Moreover, Fong also noted that while the company remains confident in the development of IMVT-1402 for Graves’ disease and other autoimmune diseases, he highlights that the market remains competitive. The analyst also raised his concern about the LNP litigation against major players, including Pfizer and Moderna, noting that adverse outcomes from the litigation could potentially impact Roivant Sciences Ltd.’s (NASDAQ:ROIV) financial health.
Roivant Sciences Ltd. (NASDAQ:ROIV) is a biotechnology company that focuses on accelerating the development and commercialization of important medicines.
5. Viatris Inc. (NASDAQ:VTRS)
Price: $10.14
Number of Hedge Fund Holders: 55
Viatris Inc. (NASDAQ:VTRS) is one of the Best Growth Stocks Under $25 to Buy Right Now. On October 15, Viatris Inc. (NASDAQ:VTRS) announced completing the acquisition of Aculys Pharma, Inc., which is a clinical-stage biopharmaceutical company.
Aculys Pharma, Inc. is commercializing innovative treatments for neurological conditions. Management noted that, as a result of this acquisition, Viatris Inc. (NASDAQ:VTRS) has received rights to develop and commercialize Pitolisant and Spydia, which are two important assets in the Central Nervous System therapy area. Moreover, the company also gained rights for Spydia Nasal Spray in Japan and certain Asia-Pacific regions, which was approved for Japan in 2025.
On the same day, Truist initiated coverage of Viatris Inc. (NASDAQ:VTRS) with a Buy rating and a $15 price target. The firm said they see an affirmative change in the company’s direction under the new leadership. Moreover, the firm also likes the company’s market leading portfolio, progressive foothold in the generics and its robust pipeline.
Viatris Inc. (NASDAQ:VTRS) is a biotechnology company with a diverse portfolio of therapies spread across a range of therapeutic areas.
4. Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Price: $19.30
Number of Hedge Fund Holders: 57
Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the Best Growth Stocks Under $25 to Buy Right Now. On October 9, Jason Gerberry from Bank of America Securities raised the firm’s price target on Teva Pharmaceutical Industries Limited (NYSE:TEVA) from $22 to $24 while keeping a Buy rating on the stock.
The analyst noted that they previewed their EPS estimates for commercial-stage biotech companies. As per the Q3 pricing volume trends on key drugs, the company does not expect any major beat or miss for Q3 in the sector.
Earlier on September 25, Teva Pharmaceutical Industries Limited (NYSE:TEVA) released its Aide Mémoires ahead of its Q3 results scheduled for November 5, 2025. As per the report, management expects full-year revenue in the range of $16.8 billion and $17.2 billion, reflecting 2% to 4% increase year-over-year. The outlook is in line with the general consensus of $16.901 billion.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) is an international drug maker that sells a range of generic, specialty, and OTC products.
3. Hewlett Packard Enterprise Company (NYSE:HPE)
Price: $22.62
Number of Hedge Fund Holders: 60
Hewlett Packard Enterprise Company (NYSE:HPE) is one of the Best Growth Stocks Under $25 to Buy Right Now. Wall Street is bullish on Hewlett Packard Enterprise Company (NYSE:HPE), since the company topped revenue estimates for FQ3 2025 on September 3.
On October 16, Asiya Merchant from Citi reiterated a Buy rating on Hewlett Packard Enterprise Company (NYSE:HPE) with a price target of $28. The analyst acknowledged the recent drop in share price following the fiscal 2028 EPS guidance, which fell below the market consensus. However, Merchant noted that the EPS guidance was in line with Citi’s expectations.
She noted the guidance to be a wise one, reflecting a conservative approach for the company’s networking segment. The analyst noted that although the segment is expected to grow modestly, it holds significant potential for faster growth as the company focuses on data center switching. She also likes the overall revenue mix of Hewlett Packard Enterprise Company (NYSE:HPE), driven by an increased mix of networking, cloud, and AI, alongside structural cost reductions and enhanced operating leverage.
Hewlett Packard Enterprise Company (NYSE:HPE) is an international edge-to-cloud company. Its offerings include cloud services, compute, high-performance computing & artificial intelligence, intelligent edge, software, and storage.
2. Pfizer Inc. (NYSE:PFE)
Price: $24.25
Number of Hedge Fund Holders: 83
Pfizer Inc. (NYSE:PFE) is one of the Best Growth Stocks Under $25 to Buy Right Now. On October 14, Pfizer Inc. (NYSE:PFE) announced positive results from its Phase 3 HER2CLIMB-05 trial.
The trial tested the kinase inhibitor TUKYSA with first-line combination therapy for patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer. The trial met its endpoints, demonstrating significant improvement in progression-free survival against the placebo.
Management noted that HER2+ breast cancer is a challenging type of cancer with many patients experiencing disease progression despite effective treatments. The results from this trial suggest that HER2CLIMB-05, along with TUKYSA, has the ability to stop disease progression, while maintaining a healthy safety profile.
Pfizer Inc. (NYSE:PFE) is a global biopharmaceutical company focused on discovering, developing, manufacturing, and marketing medicines.
1. Infosys Limited (NYSE:INFY)
Price: $16.15
Number of Hedge Fund Holders: 91
Infosys Limited (NYSE:INFY) is one of the Best Growth Stocks Under $25 to Buy Right Now. On October 17, Keith Bachman from BMO Capital lowered the firm’s price target on Infosys Limited (NYSE:INFY) from $20 to $18, while maintaining a Market Perform rating on the stock.
The analyst noted that the company posted a reasonable fiscal second quarter and also raised the bottom end of the fiscal year 2026 guidance. However, Bachman believes that the management’s commentary on the demand environment remained subdued, reflecting no improvement in smaller deals from the June quarter.
The firm remains skeptical of AI being a long-term tailwind for Infosys Limited (NYSE:INFY), but noted that the company has made several developments with regard to its AI-related demand.
Infosys Limited (NYSE:INFY) is a technology company that provides digital services and consultation to businesses, helping them navigate their digital transformations.
While we acknowledge the potential of INFY to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than INFY and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
